Camille G Wermuth

This inventor holds 24 USPTO granted patents and 1 EPO patent, primarily in Cholinergic Receptor Agonists. Top assignees: Sanofi, Elf Sanofi, Seperic. Active years: 1976-1999.

USPTO Granted Patents = 24

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 2.9

ph-index = 10

Forward Citations = 275(Granted Patents)

Company Filing History:

Societe Anonyme Sanofi

Years Active: 1976-1999

Loading Chart...

Areas of Expertise:

Cholinergic Receptors

Pyridazine Derivatives

Thiazole Compounds

Tricyclic Agonists

Pharmaceutical Preparations

Amino Derivatives

Oligopeptides

Hypertension Treatment

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5880135 - Substituted 4-phenylaminothiazoles, their process of preparation and the (1999-03-09),

2. 5821255 - Branched-amino-substituted thiazoles, processes for their preparation (1998-10-13),

3. 5656631 - Pyridazine derivatives (1997-08-12),

4. 5631255 - Pyridazine derivatives (1997-05-20),

5. 5602132 - Branched-amino-substituted thiazoles, processes for their preparation (1997-02-11),

6. 5464847 - Branched alkylamino derivatives of thiazole, processes for preparing (1995-11-07),

7. 5461053 - Pyridazine derivatives (1995-10-24),

8. 5276036 - 3-(N-azabicycloalkyl)aminopyridazine derivatives and pharmaceutical (1994-01-04),

9. 5081119 - Use of 5-alkylpyridazine derivatives as drugs active on the cholinergic (1992-01-14),

10. 4983603 - Tricyclic cholinergic receptor agonists (1991-01-08),

11. 4977152 - Novel tricyclic derivatives which are agonists of cholinergic receptors, (1990-12-11),

12. 4910199 - Imidazo[1,2-]pyridazines for cortical cholinergic deficiencies (1990-03-20),

13. 4873243 - Derivatives of 3-imino-pyridazine, process for obtaining them and (1989-10-10),

14. 4710499 - New derivatives of pyridazine active on the central nervous system (1987-12-01),

15. 4677106 - Derivatives of 4-methyl 6-phenyl pyridazine, active on the central (1987-06-30),

Title: The Innovative Contributions of Camille G Wermuth

Introduction: Camille G Wermuth, based in Strasbourg, France, is a distinguished inventor with a remarkable portfolio of 24 patents. His work primarily focuses on the development of innovative compounds that have significant applications in the medical field.

Latest Patents: Wermuth's latest patents include "Substituted 4-phenylaminothiazoles, their process of preparation" and "Branched-amino-substituted thiazoles, processes for their preparation." These inventions revolve around compounds that can be represented by a specific formula, where R1 to R5 are defined distinctly in claim 1. These compounds play a crucial role in treating pathologies involving Chronic Renal Failure (CRF), showcasing Wermuth's dedication to addressing important health issues through his research.

Career Highlights: Throughout his career, Camille G Wermuth has made significant contributions while working with renowned companies like Sanofi and Seperic. His role at these institutions has allowed him to develop groundbreaking innovations that enhance therapeutic options in the pharmaceutical industry.

Collaborations: Wermuth has collaborated with notable colleagues such as Paul Worms and Jean-Jacques Bourguignon. These partnerships have fostered an environment of creativity and innovation, allowing for the successful development of new therapeutic compounds.

Conclusion: Camille G Wermuth stands out as a prolific inventor in the realm of pharmaceuticals, contributing to advancements that benefit healthcare. His extensive patent portfolio and collaborations highlight his commitment to innovation in medical research. With a focus on impactful inventions, Wermuth continues to be a significant figure in the pursuit of solutions for critical health challenges.